NEW YORK (GenomeWeb) – Next-generation sequencing data firm OneOme has raised $1 million toward a targeted $5 million private financing round, it said in a document filed with the US Securities and Exchange Commission this week. 

The company said 15 investors had participated in the round but did not disclose their identities. OneOme CEO Troy Kopischke told GenomeWeb that the financing is the firm's first seed round and will help it accelerate the growth of its pharmacogenomics platform. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.